NCT05021328View on ClinicalTrials.gov

Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

February 5, 2025

Study Completion Date

February 5, 2025

Conditions

NSCLC

Interventions

DRUG

Toripalimab

Toripalimab 240mg, ivgtt, d1, q3w.

DRUG

Anlotinib

Anlotinib 12 mg/d, d1-14, q3w.

DRUG

SBRT 7Gy✖️5 QD

Trial Locations (1)

430079

Hubei Cancer Hospital, Wuhan

All Listed Sponsors

lead

Hubei Cancer Hospital

OTHER

NCT05021328 - Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC | Biotech Hunter | Biotech Hunter